BIGH3; CDB1; CDG2; CDGG1; CSD; CSD1; CSD2; CSD3; EBMD; LCD1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Antigen affinity purification

Store at -20 degree C. Avoid freeze / thaw cycles

Manufactured in an ISO 9001:2015 Certified Laboratory.

Small volumes of anti-BIGH3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

TGFBI, also named as BIGH3, is an adhesion protein which may play animportant role in cell-collagen interactions. TGFBI was first detected in a human lung adenocarcinoma cell line after stimulation by TGF-beta.TGFBI is secreted into the extracellular matrix (ECM) as an attachment protein. It functions mainly in cell adhesion, migration, proliferation,apoptosis, and angiogenesis. TGFBI expression is down-regulated in a variety of cancer cell lines and clinical tissue samples, and it can be used as a marker for breast cancer progression. Defects in TGFBI have been shown to be involved in several corneal dystrophies. Immunoblot analysis of TGFBI revealed both quantitative and qualitative differences between the genotypes. The secreted form of TGFBI migrates as a protein band of 75 kDa, corresponding to the predictedmolecularmass of the intact protein lacking only its signal peptide.

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP)

WB 1:200-1:2000
IHC 1:20-1:200
IF 1:50-1:500

Y79 cells were subjected to SDS PAGE followed by western blot with BIGH3 Polyclonal Antibody at dilution of 1:600

Immunohistochemical of paraffinembedded human liver cancer using BIGH3 Polyclonal Antibody at dilution of 1:50

Immunofluorescent analysis of ( -20 degree C Ethanol ) fixed HeLa cells using BIGH3 Polyclonal Antibody at dilution of 1:50 and Alexa Fluor 488-congugated AffiniPure Goat Anti- Rabbit IgG(H+L)

74,681 Da

transforming growth factor, beta-induced, 68kDa

transforming growth factor-beta-induced protein ig-h3; RGD-CAP; RGD-containing collagen-associated protein; beta ig-h3; kerato-epithelin; transforming growth factor, beta-induced, 68kD

Transforming growth factor-beta-induced protein ig-h3

BIGH3; Beta ig-h3; RGD-CAP??[Similar Products]

BGH3_HUMAN

This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The RGD motif is found in many extracellular matrix proteins modulating cell adhesion and serves as a ligand recognition sequence for several integrins. This protein plays a role in cell-collagen interactions and may be involved in endochondrial bone formation in cartilage. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion. Mutations in this gene are associated with multiple types of corneal dystrophy. [provided by RefSeq, Jul 2008]

betaIG-H3: Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation. By TGFB1. Highly expressed in the corneal epithelium.

Protein type: Secreted; Cell adhesion; Extracellular matrix; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 5q31

Cellular Component: extracellular matrix; proteinaceous extracellular matrix; extracellular space; plasma membrane; extracellular region; basement membrane; trans-Golgi network

Molecular Function: collagen binding; integrin binding; protein binding; extracellular matrix binding

Biological Process: cell proliferation; extracellular matrix organization and biogenesis; visual perception; response to stimulus; chondrocyte differentiation; negative regulation of cell adhesion; angiogenesis; cell adhesion

Disease: Corneal Dystrophy, Epithelial Basement Membrane; Corneal Dystrophy, Lattice Type Iiia; Corneal Dystrophy, Avellino Type; Corneal Dystrophy Of Bowman Layer, Type Ii; Corneal Dystrophy, Lattice Type I; Corneal Dystrophy Of Bowman Layer, Type I; Corneal Dystrophy, Groenouw Type I

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.